Quantification of tamsulosin in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry

• Autorzy: Shakya A. K. , Hakooz N. M , Arafat T. A , Abu-Awwad A. N. A , El-Ghani J. A. , Melhim M
• Języki publikacji: EN

Abstrakty

EN

A sensitive and specific high-performance liquid chromatographic-electrospray ionization tandem mass spectrometric (HPLC-ESI-MS-MS) method for quantification of tamsulosin in human plasma, using propranolol as internal standard (IS), has been developed, validated successfully, then used in a clinical study. Plasma (0.5 mL) was mixed with 50 μL 1 M sodium carbonate solution. Tamsulosin and propranolol were isolated from the mixture by liquid-liquid extraction with 7:3 ( v / v ) hexane-ethyl acetate. Reversed-phase chromatography was performed on a C 8 column at 25°C with 70:30:0.1 ( v / v ) methanol-water-formic acid as mobile phase at a flow-rate of 1.0 mL min ^-1. Quantification was achieved in positive-ion mode by monitoring the product ions at m / z 409.1 → 270.9, 228.0, and 200.0 (tamsulosin) and m / z 260.1 → 183.0 (IS). The lowest limit of quantification was 0.25 ng mL ^-1, and the calibration range was 0.25–50 ng mL ^-1. Within and between batch precision (expressed as coefficient of variation, CV) did not exceed 10.8% and accuracy was within 5.0% deviation of the nominal concentration. Recovery of tamsulosin from plasma was >83.0%. The validated method was used for clinical study of tamsulosin in human volunteers.

Słowa kluczowe

EN

tamsulosin; LC-ESI-MS-MS (ion trap); validation; bioequivalence application; clinical study

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2010
• Tom: Vol. 22, no. 1
• Strony: 99--116
• Opis fizyczny: Bibliogr. 21 poz., rys., tab.

Twórcy

autor

Shakya A. K.

• Amman University Department of Medicinal and Pharmaceutical Chemistry, Faculty of Pharmacy and Medical Sciences P.O. Box 263 Amman 19328 Jordan

autor

Hakooz N. M

• Jordan University Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy Amman Jordan

autor

Arafat T. A

• Jordan Company for Pharmaceutical Research P.O. Box 950435 Amman 11195 Jordan

autor

Abu-Awwad A. N. A

• Jordan Company for Pharmaceutical Research P.O. Box 950435 Amman 11195 Jordan

autor

El-Ghani J. A.

• Jordan Company for Pharmaceutical Research P.O. Box 950435 Amman 11195 Jordan

autor

Melhim M

• Jordan Company for Pharmaceutical Research P.O. Box 950435 Amman 11195 Jordan

Bibliografia

• [1] M.I. Wilde and D. McTavish, Drugs, 52 , 883 (1996)
• [2] M. Lee, Ann. Pharmacother., 34 , 188 (2000)
• [3] C.J. Dunn, A. Matheson, and D.M. Faude, Drugs Aging, 19 , 135 (2002)
• [4] C. Chapple and K.E. Anderson, World J. Urol., 19 , 397 (2002)
• [5] Product monograph, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT 06877, USA, February 13, 2007
• [6] S. Yamada, M. Suzuki, C. Tanaka, R. Mori, R. Kimura, O. Inagaki, K. Honda, M. Asano, T. Takenaka, and K. Kawabe, Clin. Exp. Pharmacol. Physiol., 21 , 405 (1994)
• [7] K. Honda, N. Nomose, and C. Nakagawa, J. Pharm. Pharmacol., 39 , 316 (1987)
• [8] Y. Soeishi, M. Kobori, S.I. Kobayashi, and S. Higuchi, J. Chromatogr. B, 533 , 291 (1990)
• [9] J. Macek, J. Klima, and P. Ptáček, J. Chromatogr. B, 809 , 307 (2004)
• [10] H. Matsushima, K.I. Takanuki, H. Kamimura, T. Watanabe, and S. Higuchi, J. Chromatogr. B, 695 , 317 (1997)
• [11] L. Ding, L. Li, P. Tao, J. Yang, and Z. Zheng, J. Chromatogr. B, 767 , 75 (2002)
• [12] M. Qi, P. Wang, and L. Liu, J. Chromatogr. B, 805 , 7 (2004)
• [13] N.V. Ramakrishna, K.N. Vishwottam, S. Manoj, M. Koteshwara, S. Wishu, and D.P. Varma, Biomed. Chromatogr., 19 , 709 (2005)
• [14] P.K. Rahkonen, O. Pärssinen, E. Leppänen, T. Mauriala, M. Lehtonen, and S. Auriola, J. Pharm. Biomed. Anal., 43 , 606 (2007)
• [15] S. Agarwal, K.V. Gowda, A.K. Sarkar, D. Ghosh, U. Bhaumik, T.K. Chattaraj, and T.K. Pal, Chromatographia, 67 , 893 (2008)
• [16] R. Willoughby, E. Sheehan, S. Mitrovich, A Global View of LC-MS, 2nd edn, Global View Publishing, Pittsburgh, PA, 2002
• [17] M.C. Michel, C. Korstanje, W. Krauwinkel, and M. Kuipers, Eur. Urol. Suppl., 4 , 15 (2005)
• [18] US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, Centre for Drug Evaluation and Research, Rockville, MD, 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UC M070107.pdf
• [19] B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng, Anal. Chem., 75 , 3019 (2003)
• [20] K.V. Gowda, U. Mandal, P.S. Selvan, S. Solomon, A. Ghosh, A.K. Sarkar, S. Agarwal, T.N. Rao, and T.K. Pal, J. Chromatogr., 558 , 13 (2007)
• [21] A. Van Eeckhaut, K. Lanckmans, S. Sarre, J. Smolders, and Y. Michotte, J. Chromatogr. B (2009), doi:10.1016/j.jchromb. 2009.01.003 (article in press)